Premium
Topical hydroquinone in the treatment of some hyperpigmentary disorders
Author(s) -
Amer Mohamed,
Metwalli Mohamed
Publication year - 1998
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1046/j.1365-4362.1998.00499.x
Subject(s) - melasma , medicine , hyperpigmentation , dermatology , lesion , pigmentation disorder , melanosis , surgery , melanoma , cancer research
Seventy patients (50 with melasma, 10 with freckles, and 10 with post‐inflammatory hyperpigmentation) were admitted to this trial. Treatment in the form of 4% hydroquinone (HQ) was applied topically twice daily for a maximum of 12 weeks. Patients were advised to avoid sun exposure and/or to use topical sunscreen during the entire period of treatment. All patients were examined at week 0 and at weeks 4, 8, and 12 of therapy. At each visit, the lesion size was determined and the pigmentary intensity of melasma, freckles, and the area of post‐inflammatory hyperpigmentation (PIH) relative to a non‐affected area of skin was rated on a four‐point scale: 1, no difference; 2, mild pigmentation; 3, moderate pigmentation; 4, severe pigmentation. At the last visit, the overall response was rated as excellent, good, fair, or poor.